Gina Woods, MD, shares three case scenarios of sequential treatment decision-making for long-term therapy and discusses research that can inform clinical decisions.

A 3-month course of romosozumab followed by denosumab provides similar BMD gains to those seen with 12 months of romosozumab in women with postmenopausal osteoporosis.

The primary difference between the Wegovy pill and the injection is how you take them and how often. The Wegovy pill is a daily tablet you swallow, while the Wegovy injection is a once-weekly shot you ...

Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

SHANGHAI, Dec. 16, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of ...

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and XGEVA® (denosumab) in the European Economic Area. AVT03 is approved ...

Denosumab is a widely used pharmacological treatment for osteoporosis-related bone fragility; however, its discontinuation is followed by a rapid drop in bone density. Our mixed effects linear ...